OLIMINAFlex® RESEARCH
OLIMINAFlex® research conducted by Phytogen Medical Foods has concluded with a clinical study, continuing our commitment to scientifically demonstrate its benefits.
The protocol was approved by the Ethics Committee and was carried out in accordance with good clinical practice guidelines and the Declaration of Helsinki..
Chronic pain is the most important symptom of osteoarthritis. The pain is a consequence of the degenerative process of the joints involved. The diagnosis, according to the Spanish Society of Rheumatology, is made by means of an X-ray.
It shows osteophytes, cartilage impingement and asymmetrical joint space reduction.
.
It shows osteophytes, cartilage impingement and asymmetrical joint space reduction.
.
A combination of our patented formula with hydroxytyrosol, omega 3 and curcumin, to which we add COLLAGEN, MANGANESE and VITAMIN D, which improves chronic pain in people with osteoarthritis.
OLIMINAFlex® THE BASIS OF THE STUDY
Osteoarthritis treatments include lifestyle, exercise and obesity prevention.. And also pharmacological such as paracetamol.
For those patients in whom nonsteroidal anti-inflammatory drugs are contraindicated, opioid analgesics may be used with or without acetaminophen.
.
For those patients in whom nonsteroidal anti-inflammatory drugs are contraindicated, opioid analgesics may be used with or without acetaminophen.
.
For the investigation of OLIMINAFlex® and its clinical study, patients diagnosed with osteoarthritis, over 18 years of age, with “maximum pain” in the last 24 hours greater than 4 on the visual analogue pain scale used..
Each of the components of OLIMINAFlex® has anti-inflammatory properties in vivo. Omega-3 fatty acids can inhibit the synthesis of inflammatory metabolites.
Curcumin can inactivate the NFKappa pathway and consequently dysregulate alpha TNF and other interleukins.
.
And finally, hydroxytyrosol, which has known anti-inflammatory and antioxidant effects and has been used for rheumatoid arthritis.
Curcumin can inactivate the NFKappa pathway and consequently dysregulate alpha TNF and other interleukins.
.
And finally, hydroxytyrosol, which has known anti-inflammatory and antioxidant effects and has been used for rheumatoid arthritis.
The participating investigators were: Martinez N. Herrera M, Frías L, Provencio M, Fraile R, Pérez Carrión R, Días V.
PAIN REDUCTION IN 82% OF THE PATIENTS STUDIED*.
82% of the patients analyzed showed a reduction in pain.
66% of patients have a pain reduction of more than 2 points on the VAS scale.
In PATIENTS WITH OSTEOARTHRITIS THE RESULTS ARE MORE SIGNIFICANT
- 89% of patients show pain reduction.
- 76% of patients have a reduction of more than 2 points on the VAS scale.
Positive results are also obtained in patients with chronic pain*.
- 73% of patients have pain reduction.
- In 51% the decrease in pain is greater than 2 points.
* Pain that lasts for at least three months and can be classified into one of the following categories: neuropathic, musculoskeletal, inflammatory and mechanical pain.